Chinese Hepatolgy ›› 2026, Vol. 31 ›› Issue (9): 1258-1262.

• Viral Hepatit • Previous Articles     Next Articles

The clinical characteristics of hemodialysis combined with antiviral therapy in hepatitis C patients

Liu Haiyan1, Zhao Naxin1, Ren Wenwen1, Liu Xiaoli1, Zeng Zhili1, Guo Hebing2, Xiang pan1   

  1. 1. Department of Nephrology, Beijing Ditan Hospital,Capital Medical University, Beijing 100015, China;
    2. Department of Intensive Care Medicine,Beijing Ditan Hospital,Capital Medical University, Beijing 100015, China
  • Received:2025-09-04 Online:2026-09-30 Published:2026-11-16

Abstract: Objective To analyze the clinical characteristics of patients undergoing hemodialysis who received antiviral therapy for hepatitis C viral (HCV) infection. Methods Performed a retrospective analysis on the clinical data and treatment methods of five patients with HCV infection who underwent routine hemodialysis and received antiviral therapy between January 2022 and March 2023 at the blood purification center of Beijing Ditan Hospital affiliated to Capital Medical University. Results Among the 5 patients, two had chronic glomerulonephritis, one had ischemic nephropathy combined with diabetic nephropathy, one had neurogenic bladder, and one was highly possible to have diabetic nephropathy. All patients had a history of blood transfusion. Some patients underwent HCV genotype testing. Among them, one case was genotype 1b, one case was not successfully typed, and no laboratory test reports were found for the rest of patients. Before antiviral treatment, the viral load (HCV RNA) was detected. All 5 patients had a viral load greater than 105 IU/mL. Among them, three patients received sofosbuvir-velpatasvir antiviral therapy, one patient received interferon and sofosbuvir-velpatasvir antiviral therapy sequentially, and one patient received elbasvir-grazoprevir antiviral therapy against HCV. Among the 5 patients, four had chronic hepatitis C, one had decompensated cirrhosis. All of them obtained an early response. After antiviral therapy, sustained virological response was achieved in all five patients, and no adverse reactions occurred after taking the direct-acting antiviral drugs. Conclusion Direct-acting antiviral therapy is safe and effective in patients with severe renal insufficiency undergoing hemodialysis, and has no adverse effects on renal function.

Key words: Chronic kidney disease, Hemodialysis, Hepatitis C, Sofosbuvir-velpatasvir, Elbasvir-grazoprevir